In this issue:
Switching from intravenous to subcutaneous vedolizumab in IBD
Improved bowel wall thickness on transperineal ultrasonography predicts UC treatment success
Antidepressant use in IBD
Infliximab not associated with weight gain in IBD
Early sonographic response to new therapy predicts future response/failure in IBD
BMI for predicting loss of response to anti-TNF agents in IBD
High vs. standard adalimumab induction dosing and two maintenance strategies in CD
High vs. standard adalimumab induction and maintenance dosing in UC
Obesity increases CD, not UC, risk
Two intravenous vedolizumab regimens for perianal fistulising CD
Please login below to download this issue (PDF)